Fatigue News and Research

RSS

Survival differences after docetaxel, erlotinib are EGFR dependent

Results from the DELTA trial indicate no significant differences in progression-free or overall survival after treatment with docetaxel versus erlotinib in non-small-cell lung cancer patients unselected for their epidermal growth factor receptor mutation status.

16 Jun 2014

New survey explores impact of chronic fatigue on people with rheumatoid arthritis

The National Rheumatoid Arthritis Society in collaboration with 2020health, a leading health social enterprise think tank, today announces the results from Invisible Disease: RA and Chronic Fatigue 2014, a survey of 1,954 people with Rheumatoid Arthritis (RA), to assess the impact of chronic fatigue on their capability for work, emotional and mental health as well as the overall experience of chronic fatigue caused by their RA.

16 Jun 2014

Viewpoints: VA fix comes with big pricetag; safety outside abortion clinics; questions about Medicaid eligibility

As an example of how the normally sclerotic Congress can act extremely quickly when properly motivated, both chambers passed bills this week to ameliorate the Veterans Affairs health services scandal.

16 Jun 2014

Dancing eases hip or knee pain and helps older adults move better

Dancing eases hip or knee pain and helps older adults move better, according to a small Saint Louis University study.

13 Jun 2014

Ohio State doctors treat heart failure patients with new wireless, implantable hemodynamic monitor

Doctors at The Ohio State University Wexner Medical Center are the first in the country to begin treating some heart failure patients with a new wireless, implantable hemodynamic monitor that was just approved by the U.S. Food and Drug Administration. The monitor will help physicians observe pulmonary artery pressures, optimize treatment and prevent hospitalizations.

10 Jun 2014

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

About MS booklet now available as a printed and online publication

The Multiple Sclerosis Association of America is pleased to announce that the newly published About MS booklet is now available as both a printed and online publication.

6 Jun 2014

Utz Quality Foods donates $2 million toward breast cancer survivorship program

Utz Quality Foods Inc., Executive Chairman Michael Rice and his wife Jane, a breast cancer survivor, have donated $2 million toward a breast cancer survivorship program at the Johns Hopkins Kimmel Cancer Center.

6 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV).

4 Jun 2014

Enzalutamide drug proves effective in stemming progression of prostate cancer

A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University.

3 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of 13.9 months.

2 Jun 2014

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

Fatigue is a debilitating problem for cancer patients undergoing treatment; however, it also poses a huge detriment after treatment and can significantly affect quality of life.

31 May 2014

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Fatigue News and Research

Survival differences after docetaxel, erlotinib are EGFR dependent

New survey explores impact of chronic fatigue on people with rheumatoid arthritis

Viewpoints: VA fix comes with big pricetag; safety outside abortion clinics; questions about Medicaid eligibility

Dancing eases hip or knee pain and helps older adults move better

Ohio State doctors treat heart failure patients with new wireless, implantable hemodynamic monitor

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

About MS booklet now available as a printed and online publication

Utz Quality Foods donates $2 million toward breast cancer survivorship program

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Enzalutamide drug proves effective in stemming progression of prostate cancer

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

Amgen presents extended analysis of PEAK study data at ASCO

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News